Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic and Pharmacodynamic Evaluation from an Expansion Cohort

The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic (PK) and pharmacodynamic (PD) markers with clinical outcome. In addition, a novel PD marker based on the real-time measurement of RAF...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Quintela-Fandino, Miguel, Le Tourneau, Christophe, Duran, Ignacio, Chen, Eric X., Wang, Lisa, Tsao, Ming, Bandarchi-Chamkhaleh, Bizhan, Pham, Nhu-Ann, Do, Trevor, MacLean, Martha, Nayyar, Rakesh, Tusche, Michael W., Metser, Ur, Wright, John J., Mak, Tak W., Siu, Lillian L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838726/
https://ncbi.nlm.nih.gov/pubmed/20197396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0868
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky